Regulation of lecithin-cholesterol acyltransferase reaction by acyl acceptors and demonstration of its "idling" reaction.
The mechanism for regulation of cholesterol esterification by lecithin-cholesterol acyltransferase (LCAT) was studied using the highly isolated enzyme from pig plasma. In the reaction with phosphatidylcholine small unilamellar vesicles, cholesterol, water, diacylglycerol, and lysophosphatidylcholine were all potent acceptors of an acyl group cleaved from the sn-2 position of egg phosphatidylcholine, generating cholesteryl ester, free fatty acid, triglyceride, and phosphatidylcholine, respectively. All of these reactions required activation by human apolipoprotein A-I, suggesting that this activation leads to the deacylation of phosphatidylcholine. Those acceptors competed against each other in this vesicle reaction system, and cholesterol was the most potent acyl acceptor. Lysophosphatidylcholine that was endogenously generated by deacylation of phosphatidylcholine in the first step of the LCAT reaction was also a good acyl acceptor, showing that the reaction is always partly "idling." Bovine serum albumin partially inhibited this idling reaction in a concentration-dependent manner up to 80% at 0.60 mM. The above results were essentially reproducible with high density lipoprotein, except that cholesterol is less potent than lysophosphatidylcholine in accepting the acyl group under the condition used. Unlike the apolipoprotein A-I-activated reaction, cholesterol was esterified only slightly by the LCAT reaction on low density lipoprotein and, consequently, did not compete against lysophosphatidylcholine for generation of phosphatidylcholine. Thus, apoB may activate LCAT in a very different manner from apoA-I. The rate of esterification of lysophosphatidylcholine on low density lipoprotein was one-tenth of that on the vesicles and on high density lipoprotein. Thus, LCAT is active on low density lipoprotein but mostly idling as deacylating and reacylating glycerophospholipids.
Czarnecka
H
H
Department of Medicine, University of Alberta, Edmonton, Canada.
Yokoyama
S
S
D000215:Acylation; D000818:Animals; D016632:Apolipoprotein A-I / Q000494:pharmacology; D002784:Cholesterol / Q000378:metabolism*; D002845:Chromatography; D002848:Chromatography, DEAE-Cellulose; D002852:Chromatography, Ion Exchange; D017886:Durapatite; D004789:Enzyme Activation; D006882:Hydroxyapatites; D007700:Kinetics; D008074:Lipoproteins / Q000378:metabolism*; D008244:Lysophosphatidylcholines / Q000378:metabolism; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood / Q000302:isolation & purification / Q000378:metabolism*; D010713:Phosphatidylcholines / Q000378:metabolism*; D011865:Radioisotope Dilution Technique; D013379:Substrate Specificity; D013552:Swine; D014316:Tritium; D014461:Ultracentrifugation
D016632:Apolipoprotein A-I; D006882:Hydroxyapatites; D008074:Lipoproteins; D008244:Lysophosphatidylcholines; D010713:Phosphatidylcholines; D014316:Tritium; D017886:Durapatite; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase